AB Vista is an animal nutrition technology company offering pioneering products and technical services to the global animal feed industry. With its headquarters in the UK, the company employs over 190 staff globally and has support offices worldwide.
Assess feed quality to make smarter nutritional and commercial decisions.
Measure enzyme activity to ensure consistent quality control.
Optimise the feed manufacturing process.
AB Vista is committed to facilitating discussions around animal nutrition technology and gathering experts to provide independent opinions. Our ultimate aim is to research and apply science that brings real value commercially to the animal production industry.
Stay ahead with the latest news, ideas and events.
AB Vista is committed to bringing new ways of thinking to the global feed industry. Our work attracts enquiring minds who see things differently and embrace the changing landscape – offering our clients an interested, innovative and up-to-date partner.
Friday, January 1, 2016
Econase GT is a β-glucanase that specifically targets β-glucans found within barley and oat-based diets.
READ MORE ▶
Thursday, December 17, 2015
Despite good silage-making weather in some regions of the UK and Ireland last summer, many clamps still contain large volumes of low feed value silage made under less than favourable conditions.
Wednesday, December 2, 2015
AB Vista would like to announce that Dr. Robert Van Wyhe has joined the North American technical team.
Wednesday, November 4, 2015
AB Vista has announced sales growth of more than 20% for the financial year ended 13 September 2015.
Monday, November 2, 2015
AB Vista has announced a new partnership with Milan-based distribution company Garzanti Specialties S.p.A, to supply its current enzyme portfolio to the Italian market, including the intrinsically thermostable xylanase Econase XT and modified E.coli phytase, Quantum Blue.
A regular summary of our key stories sent straight to your inbox.
Subscribe
Receive a regular summary of our key stories sent straight to your inbox.
A regular summary of our key stories sent straight to your inbox